Search the Newsreel

IGIL targets 17-19% revenue CAGR, cites SUV surge

Colgate-Palmolive Company (CL) PT Raised to $89 at Jefferies

Jefferies analyst Kaumil Gajrawala increased the price target for Colgate-Palmolive Company (NYSE: CL) to $89.00 from $88.00. The analyst maintained a rating on the stock. This article is a premium-only content piece, requiring a subscription to StreetInsider.com Premium to view in full.

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported an 8% increase in Base Business EPS for Q2 2026, reaching $0.99, driven by gross margin expansion, organic sales growth, and improved operating profit. This occurred despite a 5% decline in reported EPS due to costs from its Strategic Growth and Productivity …

Bronstein, Gewirtz & Grossman, LLC Encourages Molina Healthcare, Inc. (MOH) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (MOH) securities who bought shares before February 5, 2025, and still hold them. The investigation aims to determine if Molina and its officers engaged in corporate wrongdoing. …

Moleculin Biotech (MBRX) Registration filing Summary

Moleculin Biotech (MBRX) has filed a registration for a stock and warrant offering to raise $9.1 million, aiming to advance its late-stage cancer drug, Annamycin, for relapsed/refractory acute myeloid leukemia (AML). As of March 31, 2026, the company's net tangible book value was $4.0 …

MOH5939489 Bond Profile — Key Metrics

This article provides a bond profile for Molina Healthcare, Inc. 6.25% 15-JAN-2033 (MOH5939489), detailing key metrics such as issue date, maturity date, outstanding amount, face value, and coupon rate. It identifies Molina Healthcare as a healthcare services provider with segments including Medicaid, Medicare, and …

First Nebraska Trust Co Takes $5.16 Million Position in Colgate-Palmolive Company $CL

First Nebraska Trust Co. has acquired a new stake worth approximately $5.16 million in Colgate-Palmolive Company, purchasing 60,532 shares. This comes as Colgate-Palmolive reported strong Q2 earnings, beating analyst estimates with $0.99 EPS and a 4.9% increase in revenue. Despite positive financial results and …

Mold-Tek Packaging raises FY27 EBITDA per kg target to ₹44-45

Colgate-Palmolive (CL) Stock Sees Revenue Strength Clash With Margin Strain

Colgate-Palmolive (CL) is experiencing revenue growth, particularly in premium oral care, pet nutrition, and emerging markets, with Q2 2026 net sales up mid-single digit. However, profitability remains a concern, with a trailing 12-month net margin of 10% compared to 14.5% the previous year, and …

Colgate Palmolive (CL) Stock Trades At A Cash Flow Discount Despite An Earnings Premium

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Colgate-Palmolive stock has delivered a 30.8% return over the past five years, yet there is a split in what the valuation tools say today. The Discounted Cash …

Colgate-Palmolive Company $CL Stock Position Cut by Vestor Capital LLC

Vestor Capital LLC significantly cut its stake in Colgate-Palmolive (CL) by 95.1% in Q1 2026, selling over 30,000 shares but still retaining 1,560 shares. Despite this, other institutional investors increased their positions, and 80.41% of the stock is held by institutions. The article also …

Colgate-Palmolive (CL) Earnings Keep Fair Value In Focus

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Colgate-Palmolive (CL) drew investor attention after releasing second quarter 2026 results, reporting sales of …

Qué significan para los accionistas la reducción de los márgenes y las previsiones estables de Colgate-Palmolive (CL) para el segundo trimestre de 2026

IMDX Q1 2026 Earnings: Narrower Loss Beats Consensus, Shares Gain 1.09% - Earnings Seasonality

MBRX Q1 2026 Earnings: Wider Loss and No Revenue Trigger 61% Stock Decline - Fiscal Year Earnings

Was der Margenrückgang im zweiten Quartal 2026 und die unveränderte Prognose von Colgate-Palmolive (CL) für die Aktionäre bedeuten

Moleculin Biotech prices offering with warrants for 37,130,001 shares at $0.75 exercise price

Moleculin Biotech has priced a $9.3 million public offering that includes warrants to purchase up to 37,130,001 shares at an exercise price of $0.75 per share. The offering, which includes 12,376,667 common shares or pre-funded warrants, is expected to close around August 3, 2026. …

Molecular Partners AG (0QXX) Q4 2023 Earnings Report - Results, Call & Slides

Molecular Partners AG (0QXX) announced its Q4 2023 earnings, beating EPS and revenue expectations. The company reported an actual EPS of -CHF0.60 against a consensus of -CHF0.97, and actual revenue of CHF1.03M significantly surpassed the expected CHF400.00K. The next earnings report for Q2 2026 …

Moleculin Biotech updates Annamycin data, prices stock offering at $0.75

Moleculin Biotech has released updated preliminary blinded data from Part A of its MIRACLE trial for Annamycin, signaling stability in results despite the data remaining unblinded. Concurrently, the company priced a public offering at $0.75 per share, indicating confidence in the clinical trajectory to …

Molson Coors Beverage Company Revenue Breakdown – NYSE:TAP

Molson Coors Q2 Earnings Approaching: Will It Surprise Investors?

Molson Coors Beverage Company TAP is expected to register declines in its top and bottom lines when it reports second-quarter 2026 earnings on Aug. 6, before market open. The Zacks Consensus Estimate for revenues is pegged at $3.1 billion, indicating a 3.2% decline from …

Should Passive Income Investors Buy Colgate Palmolive Stock?

Dividend stock investors have an excellent choice with this company. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » *Stock prices …

Molecular Partners AG (MOLN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Molecular Partners AG (MOLN), focusing on its current valuation score, P/E ratio, and ranking within the Biotechnology & Medical Research industry. As of July 31, 2026, the company's valuation score is 7.34, ranking 184 out of 385, …

What Colgate-Palmolive (CL)'s Q2 2026 Margin Squeeze And Steady Guidance Mean For Shareholders

Colgate-Palmolive reported increased sales in Q2 2026 but experienced a dip in net income and earnings per share due to margin squeeze from rising costs. Despite this, the company maintained its full-year 2026 guidance for 2% to 6% net sales growth and double-digit GAAP …

Colgate-Palmolive Co reports results for the quarter ended June 30 - Earnings Summary

Colgate-Palmolive Co (CL) has released its earnings summary for the quarter that concluded on June 30. The report, sourced from Refinitiv, is available for full viewing to subscribers of TradingView's news services.

Colgate-Palmolive Co (CL) (Q2 2026) Earnings Call Highlights: Strong Organic Growth and Margin ...

This article first appeared on GuruFocus. Organic Sales Growth: Organic sales growth was reported in four of five divisions and three of four categories. Emerging Markets Sales: Sales in emerging markets were up mid-single digits, driven by India, Brazil, Mexico, and China. Free Cash …

Molecular Partners AG (MOLN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Molecular Partners AG (MOLN), highlighting its volatility, financial risk, and investment risk. The company

Colgate-Palmolive Q2 Earnings Call Highlights

Key Points Interested in Colgate-Palmolive Company? Here are five stocks we like better. Colgate-Palmolive delivered broad-based Q2 growth, with organic sales increasing across most divisions, gross margin expanding 100 basis points and free cash flow rising 18%. The company returned $1.4 billion to shareholders …

Colgate outlines 2026 gross margin as roughly flat as it expects higher raw materials and tariffs in H2

Earnings Call Insights: Colgate-Palmolive (CL) Q2 2026 MANAGEMENT VIEW * "We’re pleased to have delivered another quarter of strong top and bottom line growth, particularly in the context of continued global volatility," said (Chairman, CEO & President Noel Wallace), adding that results were "broad-based …

Moleculin Biotech (Nasdaq:MBRX) - Stock Analysis

Moleculin Biotech (MBRX) is a late-stage pharmaceutical company developing therapies for tumors and viruses, with its lead drug Annamycin undergoing Phase 2/3 trials for relapsed or refractory acute myeloid leukemia (R/R AML) and soft tissue sarcoma lung metastases. The company faces significant financial risks, …

Moleculin Biotech prices $9.3 million public offering

Moleculin Biotech (NASDAQ:MBRX) has priced a public offering of 12,376,667 shares of common stock and warrants for an additional 37,130,001 shares at $0.75 per share and warrant, totaling $9.3 million. The company plans to use the net proceeds to advance its lead drug candidate, …

Moleculin Announces Pricing of $9.3 Million Public Offering

Moleculin Biotech, Inc. announced the pricing of a $9.3 million public offering, selling 12,376,667 shares of common stock (or pre-funded warrants) and warrants to purchase up to 37,130,001 shares at $0.75 per unit. The offering is expected to close around August 3, 2026, with …

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

B. Riley has initiated coverage on 4D Molecular Therapeutics (FDMT) with a "Buy" rating and a price target of $37. The company, a late-stage biotechnology firm, is advancing several therapeutic candidates, including 4D-150 for wet age-related macular degeneration and diabetic macular edema, and 4D-710 …

Colgate-Palmolive (CL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2026, Colgate-Palmolive (CL) reported revenue of $5.36 billion, up 4.9% over the same period last year. EPS came in at $0.99, compared to $0.92 in the year-ago quarter. The reported revenue represents a surprise of +0.2% over the Zacks …

Colgate-Palmolive hält an Gewinnprognose für das Gesamtjahr 2026 fest

Colgate-Palmolive reaffirms annual sales forecast on weak North America demand

Colgate-Palmolive affirmed its annual